Tandem Diabetes Care Inc

TNDM remains in a clear medium-term downtrend following a decisive support failure and series of lower lows. While RSI is oversold and price is extended below key EMAs and SMAs, sellers maintain control and further downside toward the next structural floor is likely. Execution of bearish positions should be deferred until a corrective bounce back into the $19.40–$19.80 former support zone, where resistance can be reestablished.

• ↑Q1 2026 revenue rose 7% YoY to $247 M alongside 29K pump shipments.
• ↑Mobi tubeless system and Control IQ for Type 2 to double addressable market.
• ↓Profitability weak with negative earnings yield and poor returns.